Kymera Investor Day Presentation Deck

Short Term Exposure to MDM2 Degrader, but not SMI, is Sufficient to Commit Cells to Undergo Apoptosis Caspase 3_7/CTG Signal ● 20000 10000 3000 2000 1000 0 04 KT-253 1000 nM 100 nM 10 nM 1 nM 24 Time, hrs 48 Caspase 3_7/CTG Signal KYMERA ©2021 KYMERA THERAPEUTICS, INC. 20000 10000 3000 2000 1000 0- 04 DS-3032 1000 nM 100 nM 10 nM 1 nM 24 Time, hrs 48 Treatment Washout KYMERA R&D DAY - December 16th, 2021 Oh 4h | | P53 Levels by MSD Caspase Activity 24h Į 4 hr target coverage by KT-253 is sufficient to induce apoptosis in contrast to SMIS Supports hypothesis that intermittent dosing schedule of KT-253 can drive efficacy while increasing therapeutic index Cells Allowed to Recover 48h Į PAGE 80

View entire presentation